Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 20, 2025 19:34 ET | Source: Novo Nordisk A/S

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American Diabetes...
June 12, 2025 13:06 ET | Source: Novo Nordisk A/S

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies....
June 10, 2025 08:00 ET | Source: Novo Nordisk A/S

ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care

Novo Nordisk to present data from STEP UP trial on a higher dose of Wegovy® (semaglutide 7.2 mg) for those in need of greater weight loss Data will expand semaglutide evidence in both a clinical and...
May 16, 2025 07:19 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard...
May 16, 2025 07:02 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard...
May 14, 2025 06:59 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to develop...
May 12, 2025 02:01 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE

The REAL8 trial showed that after 52 weeks, once-weekly Sogroya® (somapacitan) had similar clinical outcomes and safety profile to once-daily Norditropin® (somatropin) in children born small for...
May 09, 2025 07:22 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 9 May 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
May 07, 2025 01:30 ET | Source: Novo Nordisk A/S

Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025

7 May 2025 - Financial report for the period 1 January 2025 to 31 March 2025 ...
May 06, 2025 08:00 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 – covering burden, and the value of treatment and...